Literature DB >> 24044795

Characterization of tumor heterogeneity using dynamic contrast enhanced CT and FDG-PET in non-small cell lung cancer.

P Veit-Haibach1, D De Ruysscher2,3, W van Elmpt2, M Das4, Martin Hüllner1, H Sharifi2, K Zegers2, B Reymen2, P Lambin2, J E Wildberger4, E G C Troost2.   

Abstract

PURPOSE: Dynamic contrast-enhanced CT (DCE-CT) quantifies vasculature properties of tumors, whereas static FDG-PET/CT defines metabolic activity. Both imaging modalities are capable of showing intra-tumor heterogeneity. We investigated differences in vasculature properties within primary non-small cell lung cancer (NSCLC) tumors measured by DCE-CT and metabolic activity from FDG-PET/CT.
METHODS: Thirty three NSCLC patients were analyzed prior to treatment. FDG-PET/CT and DCE-CT were co-registered. The tumor was delineated and metabolic activity was segmented on the FDG-PET/CT in two regions: low (<50% maximum SUV) and high (≥50% maximum SUV) metabolic uptake. Blood flow, blood volume and permeability were calculated using a maximum slope, deconvolution algorithm and a Patlak model. Correlations were assessed between perfusion parameters for the regions of interest.
RESULTS: DCE-CT provided additional information on vasculature and tumor heterogeneity that was not correlated to metabolic tumor activity. There was no significant difference between low and high metabolic active regions for any of the DCE-CT parameters. Furthermore, only moderate correlations between maximum SUV and DCE-CT parameters were observed.
CONCLUSIONS: No direct correlation was observed between FDG-uptake and parameters extracted from DCE-CT. DCE-CT may provide complementary information to the characterization of primary NSCLC tumors over FDG-PET/CT imaging.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Dynamic contrast enhanced (DCE) CT; FDG-PET; Image analysis; NSCLC; Perfusion CT imaging

Mesh:

Substances:

Year:  2013        PMID: 24044795      PMCID: PMC4667796          DOI: 10.1016/j.radonc.2013.08.032

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  34 in total

Review 1.  PET scans in radiotherapy planning of lung cancer.

Authors:  Dirk De Ruysscher; Carl-Martin Kirsch
Journal:  Radiother Oncol       Date:  2010-07-23       Impact factor: 6.280

2.  Commercial software upgrades may significantly alter Perfusion CT parameter values in colorectal cancer.

Authors:  Vicky Goh; Manu Shastry; Alec Engledow; Jonathan Reston; David M Wellsted; Jacqui Peck; Raymondo Endozo; Manuel Rodriguez-Justo; Stuart A Taylor; Steve Halligan; Ashley M Groves
Journal:  Eur Radiol       Date:  2010-10-05       Impact factor: 5.315

3.  The ESTRO Breur Lecture 2009. From population to voxel-based radiotherapy: exploiting intra-tumour and intra-organ heterogeneity for advanced treatment of non-small cell lung cancer.

Authors:  Philippe Lambin; Steven F Petit; Hugo J W L Aerts; Wouter J C van Elmpt; Cary J G Oberije; Maud H W Starmans; Ruud G P M van Stiphout; Guus A M S van Dongen; Kristoff Muylle; Patrick Flamen; André L A J Dekker; Dirk De Ruysscher
Journal:  Radiother Oncol       Date:  2010-07-19       Impact factor: 6.280

4.  Differentiation of malignant and benign pulmonary nodules with quantitative first-pass 320-detector row perfusion CT versus FDG PET/CT.

Authors:  Yoshiharu Ohno; Hisanobu Koyama; Keiko Matsumoto; Yumiko Onishi; Daisuke Takenaka; Yasuko Fujisawa; Takeshi Yoshikawa; Minoru Konishi; Yoshimasa Maniwa; Yoshihiro Nishimura; Tomoo Ito; Kazuro Sugimura
Journal:  Radiology       Date:  2011-02       Impact factor: 11.105

5.  Tracer kinetic model selection for dynamic contrast-enhanced computed tomography imaging of prostate cancer.

Authors:  Johannes G Korporaal; Marco van Vulpen; Cornelis A T van den Berg; Uulke A van der Heide
Journal:  Invest Radiol       Date:  2012-01       Impact factor: 6.016

6.  Reproducibility of perfusion parameters obtained from perfusion CT in lung tumors.

Authors:  Chaan S Ng; Adam G Chandler; Wei Wei; Ella F Anderson; Delise H Herron; Chusilp Charnsangavej; Razelle Kurzrock
Journal:  AJR Am J Roentgenol       Date:  2011-07       Impact factor: 3.959

Review 7.  Targeting hypoxia in cancer therapy.

Authors:  William R Wilson; Michael P Hay
Journal:  Nat Rev Cancer       Date:  2011-06       Impact factor: 60.716

8.  Assessment of non-small cell lung cancer perfusion: pathologic-CT correlation in 15 patients.

Authors:  Nunzia Tacelli; Martine Remy-Jardin; Marie-Christine Copin; Arnaud Scherpereel; Eric Mensier; Sophie Jaillard; Jean-Jacques Lafitte; Ernst Klotz; Alain Duhamel; Jacques Remy
Journal:  Radiology       Date:  2010-09-15       Impact factor: 11.105

9.  Monitoring response to antiangiogenic therapy in non-small cell lung cancer using imaging markers derived from PET and dynamic contrast-enhanced MRI.

Authors:  Adrianus J de Langen; Vivian van den Boogaart; Mark Lubberink; Walter H Backes; Johannes T Marcus; Harm van Tinteren; Jan Pruim; Boudewijn Brans; Pieter Leffers; Anne-Marie C Dingemans; Egbert F Smit; Harry J M Groen; Otto S Hoekstra
Journal:  J Nucl Med       Date:  2010-12-13       Impact factor: 10.057

Review 10.  Molecular mechanisms and clinical applications of angiogenesis.

Authors:  Peter Carmeliet; Rakesh K Jain
Journal:  Nature       Date:  2011-05-19       Impact factor: 49.962

View more
  16 in total

1.  A comparison study of dual-energy spectral CT and 18F-FDG PET/CT in primary tumors and lymph nodes of lung cancer.

Authors:  Osman Kupik; Yavuz Metin; Gülnihan Eren; Nurgul Orhan Metin; Medeni Arpa
Journal:  Diagn Interv Radiol       Date:  2021-03       Impact factor: 2.630

2.  Use of patient outcome endpoints to identify the best functional CT imaging parameters in metastatic renal cell carcinoma patients.

Authors:  Jill Rachel Mains; Frede Donskov; Erik Morre Pedersen; Hans Henrik Torp Madsen; Jesper Thygesen; Kennet Thorup; Finn Rasmussen
Journal:  Br J Radiol       Date:  2018-01-02       Impact factor: 3.039

3.  CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma.

Authors:  Thibaud P Coroller; Patrick Grossmann; Ying Hou; Emmanuel Rios Velazquez; Ralph T H Leijenaar; Gretchen Hermann; Philippe Lambin; Benjamin Haibe-Kains; Raymond H Mak; Hugo J W L Aerts
Journal:  Radiother Oncol       Date:  2015-03-04       Impact factor: 6.280

Review 4.  Image-derived biomarkers and multimodal imaging strategies for lung cancer management.

Authors:  Alexander W Sauter; Nina Schwenzer; Mathew R Divine; Bernd J Pichler; Christina Pfannenberg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-01-09       Impact factor: 9.236

5.  Dual-Phase Dual-Energy CT in Patients Treated with Erlotinib for Advanced Non-Small Cell Lung Cancer: Possible Benefits of Iodine Quantification in Response Assessment.

Authors:  Jan Baxa; Tana Matouskova; Gabriela Krakorova; Bernhard Schmidt; Thomas Flohr; Martin Sedlmair; Jiri Bejcek; Jiri Ferda
Journal:  Eur Radiol       Date:  2015-11-12       Impact factor: 5.315

Review 6.  Functional imaging for radiotherapy treatment planning: current status and future directions-a review.

Authors:  D Thorwarth
Journal:  Br J Radiol       Date:  2015-04-01       Impact factor: 3.039

Review 7.  Characterization of the Tumor Microenvironment and Tumor-Stroma Interaction by Non-invasive Preclinical Imaging.

Authors:  Nirilanto Ramamonjisoa; Ellen Ackerstaff
Journal:  Front Oncol       Date:  2017-01-31       Impact factor: 6.244

8.  Pulmonary Functional Imaging for Lung Adenocarcinoma: Combined MRI Assessment Based on IVIM-DWI and OE-UTE-MRI.

Authors:  Hui Liu; Liyun Zheng; Gaofeng Shi; Qian Xu; Qi Wang; Hongshan Zhu; Hui Feng; Lijia Wang; Ning Zhang; Meng Xue; Yongming Dai
Journal:  Front Oncol       Date:  2021-07-06       Impact factor: 6.244

Review 9.  Review of photoacoustic flow imaging: its current state and its promises.

Authors:  P J van den Berg; K Daoudi; W Steenbergen
Journal:  Photoacoustics       Date:  2015-08-13

10.  Multiparametric imaging of patient and tumour heterogeneity in non-small-cell lung cancer: quantification of tumour hypoxia, metabolism and perfusion.

Authors:  Wouter van Elmpt; Catharina M L Zegers; Bart Reymen; Aniek J G Even; Anne-Marie C Dingemans; Michel Oellers; Joachim E Wildberger; Felix M Mottaghy; Marco Das; Esther G C Troost; Philippe Lambin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-09-04       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.